These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34916417)

  • 21. Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH.
    Pluta RM
    Neurol Res; 2006 Oct; 28(7):730-7. PubMed ID: 17164036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of an endogenous inhibitor of nitric oxide synthase with cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
    Jung CS; Oldfield EH; Harvey-White J; Espey MG; Zimmermann M; Seifert V; Pluta RM
    J Neurosurg; 2007 Nov; 107(5):945-50. PubMed ID: 17977265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes.
    Böger RH; Bode-Böger SM; Tsao PS; Lin PS; Chan JR; Cooke JP
    J Am Coll Cardiol; 2000 Dec; 36(7):2287-95. PubMed ID: 11127475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asymmetric dimethylarginine--mechanisms and targets for therapeutic management.
    Vladimirova-Kitova LG
    Folia Med (Plovdiv); 2008; 50(1):12-21. PubMed ID: 18543783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of asymmetric dimethylarginine, arginine, and carnitine metabolism in pediatric sepsis.
    Weiss SL; Haymond S; Ralay Ranaivo H; Wang D; De Jesus VR; Chace DH; Wainwright MS
    Pediatr Crit Care Med; 2012 Jul; 13(4):e210-8. PubMed ID: 22460770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase.
    MacAllister RJ; Parry H; Kimoto M; Ogawa T; Russell RJ; Hodson H; Whitley GS; Vallance P
    Br J Pharmacol; 1996 Dec; 119(8):1533-40. PubMed ID: 8982498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of asymmetric and symmetric dimethylarginines in renal disease.
    Schwedhelm E; Böger RH
    Nat Rev Nephrol; 2011 May; 7(5):275-85. PubMed ID: 21445101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ammonia Reduces Intracellular Asymmetric Dimethylarginine in Cultured Astrocytes Stimulating Its y⁺LAT2 Carrier-Mediated Loss.
    Milewski K; Bogacińska-Karaś M; Fręśko I; Hilgier W; Jaźwiec R; Albrecht J; Zielińska M
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of asymmetric dimethylarginine (ADAMA), the endogenous nitric oxide (NO) synthase inhibitor, to the pathogenesis of gastric mucosal damage.
    Szlachcic A; Krzysiek-Maczka G; Pajdo R; Targosz A; Magierowski M; Jasnos K; Drozdowicz D; Kwiecien S; Brzozowski T
    Curr Pharm Des; 2013; 19(1):90-7. PubMed ID: 22950506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Nitric Oxide and Sympathetic Control in Cerebral Autoregulation in the Setting of Subarachnoid Hemorrhage and Traumatic Brain Injury.
    Guo ZN; Shao A; Tong LS; Sun W; Liu J; Yang Y
    Mol Neurobiol; 2016 Aug; 53(6):3606-3615. PubMed ID: 26108186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?
    Chan NN; Chan JC
    Diabetologia; 2002 Dec; 45(12):1609-16. PubMed ID: 12488950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?
    Czarnecka A; Milewski K; Zielińska M
    Neurochem Res; 2017 Mar; 42(3):750-761. PubMed ID: 27885576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel mass spectrometry-based method for simultaneous determination of asymmetric and symmetric dimethylarginine, l-arginine and l-citrulline optimized for LC-MS-TOF and LC-MS/MS.
    Wiśniewski J; Fleszar MG; Piechowicz J; Krzystek-Korpacka M; Chachaj A; Szuba A; Lorenc-Kukula K; Masłowski L; Witkiewicz W; Gamian A
    Biomed Chromatogr; 2017 Nov; 31(11):. PubMed ID: 28436051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The emerging role of symmetric dimethylarginine in vascular disease.
    Mangoni AA
    Adv Clin Chem; 2009; 48():73-94. PubMed ID: 19803415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxic Dimethylarginines: Asymmetric  Dimethylarginine (ADMA) and Symmetric  Dimethylarginine (SDMA).
    Tain YL; Hsu CN
    Toxins (Basel); 2017 Mar; 9(3):. PubMed ID: 28272322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevation of serum asymmetrical and symmetrical dimethylarginine in patients with advanced glaucoma.
    Javadiyan S; Burdon KP; Whiting MJ; Abhary S; Straga T; Hewitt AW; Mills RA; Craig JE
    Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):1923-7. PubMed ID: 22395885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.
    Leiper J; Vallance P
    Cardiovasc Res; 1999 Aug; 43(3):542-8. PubMed ID: 10690326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
    Toutouzas K; Riga M; Stefanadi E; Stefanadis C
    Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH; Bode-Böger SM
    Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease.
    Papageorgiou N; Androulakis E; Papaioannou S; Antoniades C; Tousoulis D
    Amino Acids; 2015 Sep; 47(9):1741-50. PubMed ID: 26123985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.